pertagen
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
1
Earliest trial started Oct 27, 2016 (NCT02946190)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Bordetella pertussisImmunity, active
Bordetella pertussis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pertagen
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06803524 | Phase 4 | May 13, 2025 | BioNet-Asia Co., Ltd., Mahidol University |
| NCT05193734 | Phase 2/Phase 3 (Phase 3) | Feb 7, 2022 | University of Geneva, University of Genoa |
| NCT02946190 | Phase 2 | Oct 27, 2016 | BioNet-Asia Co., Ltd., University of Geneva |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioNet-Asia Co., Ltd. | For profit | 2 | 0 | 2 | 2016 |
| University of Geneva | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Mahidol University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Genoa | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1